CLS Q3 2022: Exciting times ahead - Redeye - Börskollen
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

Aktieanalys

CLS Q3 2022: Exciting times ahead - Redeye

{newsItem.title}

Redeye provides an updated view of CLS after its Q3 2022 report and directed issue announcement. Although the report brought no major surprises in our view, our case review has prompted us to make changes in our market, probability rate, and capital need assumptions, changing our base case from SEK1.6 to SEK1.4. However, we believe exciting times are ahead as we expect sales to ramp up from next year.

Länk till analysen i sin helhet: https://www.redeye.se/research/864071/cls-q3-2022-exciting-times-ahead?utm_source=finwire&utm_medium=RSS

Nyheter om Clinical Laserthermia

Läses av andra just nu

Om aktien Clinical Laserthermia

Senaste nytt